Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Onyx Pharmaceuticals, Inc. (ONXX), Alexion Pharmaceuticals, Inc. (ALXN): 3 Biotechs That Could Be Bought Out This Year

Page 1 of 2

Buyout! The word gets biotech investors’ blood flowing and their hearts racing. Mere rumors that a biotech stock could get bought out can send shares surging.

Chances are that a few biotech companies will be scooped up by larger players over the coming months. Here are three biotechs that could possibly be bought out by the end of the year.

1. Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)

This one’s virtually a no-brainer. A few weeks ago, Amgen, Inc. (NASDAQ:AMGN) made an unsolicited offer for Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX). Although Onyx rejected Amgen’s bid of $120 per share as being too low, that wasn’t the end of the story.

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) decided it liked the attention from Amgen, Inc. (NASDAQ:AMGN) and “interest received from other third parties,” so it commissioned its financial adviser to explore other opportunities for a sale. Depending on which analyst you’re listening to, the biotech could bring as low as $145 per share and as high as $180 per share.

Several potential buyers have been floated — by pundits, not by the company itself. German drugmaker Bayer and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) already work closely together, co-marketing Nexavar. Pfizer Inc. (NYSE:PFE) also has a connection with the biotech through its licensing of breast cancer drug palbociclib. Of course, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) won’t limit its options to big companies with which it currently works.

2. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. (ALXN)Despite all of the buzz, I won’t say that a sale of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a done deal just yet. Roche is reportedly looking to finance a buyout of Alexion, but the possibility exists that the high price tag could scuttle those plans. On the other hand, we would be remiss without including Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in our list of potential biotech buyouts.

Roche threw in the towel last year on a potential acquisition of Illumina, Inc. (NASDAQ:ILMN) due to price. The company hasn’t shied away from big deals, though. It bought Genentech in 2009 for $46.8 billion. However, that buyout was for 17 times EBITDA. Piper Jaffray says that an acquisition of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) could cost 61 times EBITDA.

Valuation concerns aside, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) makes an attractive target for Roche. Soliris, which treats two rare blood diseases, enjoys marketing exclusivity as an orphan drug and ranks as one of the most expensive treatments in the world. Alexion also continues to experience strong growth from Soliris, with revenue increasing 38.5% year-over-year last quarter.

3. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

There aren’t any known deals in the works for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), but it wouldn’t be surprising if acquisition stories emerge in the not-too-distant future. Several factors could contribute to the small biotech ending up as a target for a larger player.

Acadia received great news from the Food and Drug Administration in April. The FDA told the company that another planned phase 3 trial wouldn’t be needed for pursuing approval of pimavanserin, which targets treatment of Parkinson’s disease psychosis, or PDP. As a result, Acadia anticipates submitting a New Drug Application, or NDA, for the drug by the end of 2014.

Pimavanserin also holds potential to treat Alzheimer’s disease psychosis, which is similar in several aspects to PDP, as well as schizophrenia. Analyst Jason Napodano projects that worldwide peak sales for all indications could exceed the $2 billion mark. With Acadia’s market cap now at a little over $1.5 billion, the company could be a good buy for a larger organization if these estimates are even close to accurate.

Page 1 of 2
Loading Comments...